Woodcock, Noubar and Genmab’s dealmaking: a BioCentury podcast

On the latest BioCentury This Week podcast, BioCentury’s editors discuss key takeaways from two exclusive Q&As with Acting FDA Commissioner Janet Woodcock and Flagship Pioneering’s founder and CEO Noubar Afeyan, and highlight what Genmab is seeking in its next deals. 

In an interview with Washington Editor Steve Usdin, Woodcock said justification for FDA’s accelerated approval of Aduhelm aducanumab from Biogen Inc. (NASDAQ:BIIB) for Alzheimer’s disease will be provided in review documents that will be released soon. “That’s going to be really important and really interesting to see if FDA actually justifies why it’s all in on the amyloid hypothesis,” says Usdin. ...